/
Oncology
Advanced Malignant Solid Tumors
39
Pipeline Programs↗
39
Active Trials↗
42
Companies Involved↗
Advanced Malignant Solid Tumors is a moderately active landscape with 39 programs across 42 companies. The most active players are Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Qilu Pharmaceutical Co., Ltd., Tasly Biopharmaceuticals Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
JPhase 1
Phase 2TPhase 2MPhase 2CPhase 2CPhase 1
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2 programs
Qilu Pharmaceutical Co., Ltd.
1 program
Tasly Biopharmaceuticals Co., Ltd.
1 program
Minghui Pharmaceutical (Hangzhou) Ltd
1 program
CSPC Megalith Biopharmaceutical Co.,Ltd.
1 program
Chongqing Precision Biotech Co., Ltd
1 program
Pipeline
Programs by Phase
Preclinical10
Phase 114
Phase 215
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
33programs
Small molecule1958%
Cell therapy721%
Monoclonal antibody515%
Vaccine26%
Modality classified for 90% of 39 pipeline programs.
Analysis
Trial Status
93
clinical trials
Recruiting27 · 29%
Completed22 · 24%
Unknown status21 · 23%
Terminated10 · 11%
Not yet recruiting9 · 10%
Active, not recruiting3 · 3%
Other1 · 1%
Clinical Trials
Trial Activity
93 trials
A Single-Arm, Open-Label, Dose-Escalation/Cohort-Expansion Phase Ia/Ib Study to Evaluate Safety, Tolerability, PK/PD Profiles, and Preliminary Efficacy of TPD3310 Injection in Advanced Malignant Solid Tumor Patients
Recruiting·TTAIBIDI PHARMACEUTICAL TECHNOLOGY(SHIJIAZHUANG) CO.,LTD.·Phase 1·NCT07368127·112 enrolled
a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors
Recruiting·—·Phase 1·NCT06878612·9 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)